Comparison · NCT01114880-b3dbfc6b
Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS40 Response Criteria
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Adalimumab/Adalimumab vs Placebo/Adalimumab: Number of Participants Meeting the ASAS40 Response Criteria. Trial comparisons, record NCT01114880-b3dbfc6b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01114880-b3dbfc6b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.598 | 0.533 | 0.66 | wilson | |
| Risk in group 2 | 0.558 | 0.466 | 0.646 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0407 | -0.0691 | 0.152 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.882 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.748 | 1.87 | log | |
| Number needed to treat, for one more participant with the outcome on Adalimumab/Adalimumab than on Placebo/Adalimumab | 24.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Adalimumab/Adalimumab | Blinded adalimumab from Week 0 to Week 10; open-label adalimumab from Week 12 to Week 22 | 134 | 224 | OG000 |
| Group 2 | Placebo/Adalimumab | Blinded Placebo from Week 0 to Week 10; open-label adalimumab from Week 12 to Week 22 | 63 | 113 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Meeting the ASAS40 Response Criteria
- Description
An ASAS40 responder had improvement of 40% or more and absolute improvement of 20 units or more (on a scale of 0 \[least\] to 100 \[worst\]) from Baseline in at least 3 of the 4 domains identified above for the ASAS20. In addition, there must have been an absence of deterioration in the potential remaining domain, where deterioration was defined as a net worsening of greater than 0 units (on a scale of 0 to 100).
- Time frame
- Week 24
- Population
- ITT analysis set, missing data imputed by NRI
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
- NCT number
- NCT01114880
- Phases
- PHASE3
- Conditions
- Ankylosing Spondylitis
- Interventions
- adalimumab, placebo
- Lead sponsor
- Abbott
- Results first posted
- 2011-11-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01114880?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01114880-b3dbfc6b